Show simple item record

dc.contributor.authorBrazier, MW
dc.contributor.authorWall, VA
dc.contributor.authorBrazier, BW
dc.contributor.authorMasters, CL
dc.contributor.authorCollins, SJ
dc.date.available2014-05-21T19:03:48Z
dc.date.issued2009-02-01
dc.identifierhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000263582500013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4d813f4571fa7d6246bdc0dfeca3a1c
dc.identifier.citationBrazier, M. W., Wall, V. A., Brazier, B. W., Masters, C. L. & Collins, S. J. (2009). Therapeutic interventions ameliorating prion disease. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 7 (1), pp.83-105. https://doi.org/10.1586/14787210.7.1.83.
dc.identifier.issn1478-7210
dc.identifier.urihttp://hdl.handle.net/11343/25654
dc.descriptionC1 - Journal Articles Refereed
dc.description.abstractOf the many unresolved issues in relation to prion diseases, effective treatments remain an elusive exigency, although some progress has been made. This review describes disease-ameliorating therapeutic strategies reported to date in animal models of prion disease, as well as providing a brief overview of selected completed human treatment trials. Included in vivo studies have been broadly dichotomized according to the time of introduction of the treatment in relation to animal inoculation and also according to their possible principal mechanism of action, although the latter is not always entirely clear, and often there is likely to be more than one mechanism. Consequent to the pathogenic primacy of cellular prion protein (PrP(c))-to-scrapie PrP(c) (PrP(sc)) conversion, most reported treatments appear to directly target this replication process, although various other strategies, such as depletion of reaction substrates and abrogation of downstream effector pathways, have been utilized. Many factors, including experimental design, militate against reliable extrapolation of study results to the routine clinical setting or limit easy translational application to human disease. Notably problematic are approaches wherein benefit has been shown but the treatment was initiated before, at or soon after inoculation of experimental animals.
dc.languageEnglish
dc.publisherTAYLOR & FRANCIS LTD
dc.subjectClinical Microbiology; Microbiology not elsewhere classified; Nervous System and Disorders; Nervous System and Disorders
dc.titleTherapeutic interventions ameliorating prion disease
dc.typeJournal Article
dc.identifier.doi10.1586/14787210.7.1.83
melbourne.peerreviewPeer Reviewed
melbourne.affiliationThe University of Melbourne
melbourne.affiliation.departmentPathology
melbourne.source.titleEXPERT REVIEW OF ANTI-INFECTIVE THERAPY
melbourne.source.volume7
melbourne.source.issue1
melbourne.source.pages83-105
dc.research.codefor110303
dc.research.coderfcd270399
dc.research.codeseo1998730104
dc.research.codeseo2008920111
melbourne.publicationid120890
melbourne.elementsid308857
melbourne.contributor.authorWALL, VANESSA
melbourne.contributor.authorMasters, Colin
melbourne.contributor.authorCollins, Steven
melbourne.contributor.authorBRAZIER, MARCUS
dc.identifier.eissn1744-8336
melbourne.accessrightsThis item is currently not available from this repository


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record